Worldwide Novel Ocular Drug Delivery Devices Industry to 2030 – Featuring Aciont, AcuFocus and Allergan Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Novel Ocular Drug Delivery Devices Market: Focus on Implants, Inserts and Punctal Plugs – Distribution by Type of Drug Delivery Device, Target Indications, Type of Product and Key Geographies: Industry Trends and Global Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current market landscape and the likely adoption of novel ocular drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain.

According to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and/or could have been prevented. It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment/care.

Considering the aforementioned facts, there is a rise in demand for effective therapeutic interventions for the treatment of ocular diseases, in order to prevent complete vision loss. Conventionally, ocular diseases have been treated through surgery, laser or pharmacological interventions (such as anti-angiogenic drugs). However, these treatment options are associated with several limitations, including side effects of intravitreal injections and conventional surgeries, poor drug bioavailability at the target tissue site and need for frequent drug administration to maintain efficacy for a longer duration.

In addition, at present, more than 90% of the marketed ophthalmic formulations are available in the form of eye drops that mainly target diseases related to anterior segment of the eye. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases.

Owing to the aforementioned concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of drugs, while overcoming the existing challenges. In fact, over 1,100 patents related to novel ocular drug delivery devices have been filed/granted in the past few years, demonstrating the continued innovation being carried out in this domain. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity of novel ocular drug delivery device developers. Driven by the increasing patient population and introduction of novel and advanced ocular drug delivery devices, this market is anticipated to witness steady growth in the coming years.

Key Questions Answered

• Who are the leading novel ocular drug delivery device developers?
• Which are the popular types of novel ocular drug delivery devices available in this market?
• What are the key challenges faced by stakeholders engaged in this domain?
• What types of partnership models are commonly being adopted by stakeholders in this industry?
• Who are the key investors in this domain?
• How is the intellectual property landscape in this field likely to evolve in the foreseen future?
• What are the factors that are likely to influence the evolution of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Companies Mentioned

• 20/20 OptimEyes Technologies
• 23andMe
• Aciont
• AcuFocus
• Adaptive Biotechnologies
• Aerie Pharmaceuticals
• Aero Pump
• AffaMed Therapeutics
• Akarna Therapeutics
• Alcon
• Alcon
• Alibaba Health Information Technology
• Alimera Sciences
• Allergan
• Alta Partners
• Amorphex Therapeutics
• Angiotech Pharmaceuticals
• Anthrogenesis
• Ascension Ventures
• Atalanta
• Avedro
• Avizorex Pharma
• Bausch & Lomb
• Brien Holden Vision Institute (BHVI)
• BioHealthWays
• Bionic Vision Technologies
• Brandon Capital partners
• BTG
• Burrill & Company
• Cella Therapeutics
• Children’s National Hospital
• ChromaGen Vision
• Cirle
• Clarus Ventures
• Clearside Biomedical
• Corporate Renaissance Group
• D. Western Therapeutics Institute
• Deerfield
• DelSiTech
• Department of Defense
• Domain Associates
• DSM
• Envisia Therapeutics
• Escalon Medical
• EW Healthcare Partners
• Eximore
• EYE-GO
• EyePoint Pharmaceuticals
• Eyevensys
• FB VISION
• And Many More Companies!

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET OVERVIEW

5. CASE STUDY: TYPES OF NOVEL OCULAR DRUG DELIVERY DEVICES

6. COMPANY PROFILES

7. CLINICAL TRIAL ANALYSIS

8. PARTNERSHIPS AND COLLABORATIONS

9. FUNDING AND INVESTMENT ANALYSIS

10. PATENT ANALYSIS

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/55nqyz

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900